olmesartan has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, S; Jiang, F; Kim, GJ; Melgoza, A | 1 |
| Abe, E; Azushima, K; Hashimoto, T; Kamimura, D; Kinguchi, S; Nakano, M; Sano, D; Suzuki, T; Taguchi, S; Tamura, K; Tanaka, S; Tsukamoto, S; Urate, S; Wakui, H; Yamada, T; Yamaji, T; Yamashita, A | 1 |
2 other study(ies) available for olmesartan and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The effect of renin-angiotensin-aldosterone system inhibitors on organ-specific ace2 expression in zebrafish and its implications for COVID-19.
Topics: Amides; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Brain; COVID-19; Down-Regulation; Fumarates; Gills; Humans; Imidazoles; Liver; Models, Animal; SARS-CoV-2; Tetrazoles; Up-Regulation; Zebrafish | 2021 |
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease.
Topics: Adenine; Angiotensin-Converting Enzyme 2; Animals; Aristolochic Acids; COVID-19; Disease Models, Animal; Down-Regulation; Humans; Imidazoles; Kidney; Mice; Mice, Inbred C57BL; Organ Specificity; Renal Insufficiency, Chronic; SARS-CoV-2; Tetrazoles | 2021 |